Enhancing Efficacy of Biologic-DT Liver Assist Device

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$54,000.00
Award Year:
1994
Program:
SBIR
Phase:
Phase I
Contract:
1 R43 DK47744-1,
Agency Tracking Number:
25017
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Hemocleanse, Inc.
2701-B Kent Avenue, West Lafayette, IN, 47906
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 Stephen Ash
 (317) 463-9540
Business Contact
Phone: () -
Research Institution
N/A
Abstract
Acute hepatic failure (AHF) with Stage 4 coma is a serious illness with over 60% mortality whentreated with supportive therapy. The BioLogic-DT is an extracorporeal liver support device in whichblood passes through cellulosic packages with a suspension of powdered charcoal and cation exchangersorbents on the opposite side. This device effectively removes many organic toxins of 100-300 m.w.including aromatic amino acids, but removes only small amounts of ammonia. It does not increasebranch chain amino concentrations in blood. Nonetheless, over 80% of liver failure patients improvephysiologically and neurologically during treatment with the device; most recover liver function orproceed to liver transplant. In the current study, we will add acid-filled liquid membrane capsules to thesorbent suspension to remove ammonia, and will pre-load the charcoal with branch chain amino acidsto return these amino acids to the patient during treatment. In vitro tests will determine.the effect ofthese sorbent changes on ammonia removal and branch-chain generation, and will determine whetherthere is any loss of organic toxin removal. Phase II clinical studies will determine whether the newchemical functions of the sorbent improve the treatment of patients with hepatic coma.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government